News about general reimbursement of medicines

  • Reassessment of reimbursement status

    | 18 December 2006 |

    This summer, the Danish Medicines Agency will begin the periodic reassessment of reimbursement status of medicinal products. Over a 5-year period, the reimbursement status of all medicinal products will be reassessed to ensure that the medicinal products having been granted general reimbursement still meet the required criteria and that medicinal products which have not been granted general reimbursement do not meet the criteria.

  • Consultation on recommended changes of the reimbursement status of lipid-lowering medicinal products

    | 18 December 2006 |

    At several meetings, the Reimbursement Committee has discussed the reimbursement status of lipid-lowering medicinal products. In its recommendation of 7 September 2006 for the Danish Medicines Agency, the Committee suggests a change of reimbursement status for these medicinal products.

  • Reassessment of reimbursement status of ATC-groups C01, C04 and C05

    | 18 December 2006 |

    At its meetings on 19 September and 7 November 2006, the Reimbursement Committee discussed the reimbursement status of medicinal products in ATC-groups.

  • Reassessment of reimbursement status for medicinal products for hypertension

    | 18 December 2006 |

    In March 2006, the Danish Medicines Agency contacted a number of scientific societies to clarify certain aspects of the treatment of hypertension in Denmark.

  • Reassessment of subgroups in ATC group C

    | 24 April 2006 |

    The Danish Medicines Agency is just beginning to reassess the subgroups in ATC group C, medicinal products for the cardiovascular system, and for the first three months of 2006 the agency expects to be working with the following six subgroups.

  • Letter to scientific societies on treatment of hypertension

    | 24 April 2006 |

    As part of the reassessment concerning medicinal products' reimbursement status, the Danish Medicines Agency has begun looking at reimbursement status of medicinal products for hypertension.